bexagliflozin CAS 1118567-05-7

bexagliflozin CAS 1118567-05-7

Identification

CAS Number

1118567-05-7

Name

bexagliflozin

Synonyms

(1S)-1,5-Anhydro-1-(4-chlor-3-{4-[2-(cyclopropyloxy)ethoxy]benzyl}phenyl)-D-glucitol [German] [ACD/IUPAC Name]
(1S)-1,5-Anhydro-1-(4-chloro-3-{4-[2-(cyclopropyloxy)ethoxy]benzyl}phenyl)-D-glucitol [ACD/IUPAC Name]
(1S)-1,5-Anhydro-1-(4-chloro-3-{4-[2-(cyclopropyloxy)éthoxy]benzyl}phényl)-D-glucitol [French] [ACD/IUPAC Name]
1118567-05-7 [RN]
bexagliflozin [INN] [USAN]
bexagliflozina [Spanish] [INN]
bexagliflozine [French] [INN]
bexagliflozinum [Latin] [INN]
D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-, (1S)- [ACD/Index Name]
EGT0001442
Egt-1442
EGT1442
THR1442
THR-1442
Бексаглифлозин [Russian] [INN]
بيكساغليفلوزين [Arabic] [INN]
贝沙格列净 [Chinese] [INN]
(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol
(2S,3R,4R,5S,6R)-2-(4-chloro-3-{[4-(2-cyclopropoxyethoxy)phenyl]methyl}phenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
bexagliflozina
bexagliflozine
bexagliflozinum
Bexgliflozin (EGT1442)
MFCD22628819
MFCD28100944
бексаглифлозин
بيكساغليفلوزين
贝沙格列净

SMILES

c1cc(ccc1Cc2cc(ccc2Cl)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)OCCOC4CC4

StdInChI

InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1

StdInChIKey

BTCRKOKVYTVOLU-SJSRKZJXSA-N

Molecular Formula

C24H29ClO7

Molecular Weight

464.936

MDL Number

MFCD28100944

Properties

Safety Data

Symbol

exclamation-mark-jpgGHS07

Signal Word

Warning

Hazard statements

H302-H315-H319-H335

Precautionary Statements

P261-P305+P351+P338

WGK Germany

3

MSDS Download

Specifications and Other Information of Our

Known Application

Bexagliflozin is a GLT2 inhibitor and a new type of hypoglycemic drug. It can inhibit SGLT2 in renal tubular epithelial cells, leading to an increase in the body’s caloric consumption, reducing fluid retention and increasing urinary glucose excretion. SGLT2 inhibitors have obvious advantages over other drugs: (1) they can reduce pre- and post-meal blood glucose levels (not all drugs can reduce both at the same time); (2) because they do not stimulate insulin secretion, all The risk of hypoglycemia for users is relatively low; (3) Due to its main effect on renal tubules, it produces a diuretic effect, thereby reducing systolic blood pressure; (4) Studies have found that SGLT2 inhibitors have a therapeutic effect on diabetic nephropathy.

In short, SGLT2 inhibitors have the functions of lowering blood sugar, weight loss, and lowering blood pressure, and have clear cardiovascular and renal protective effects.

General View of Documents

This product is sold exclusively through our sales company Watson International Limited, and please click the link below for details (https://www.watson-int.com/).